The 36-month beta value for JAGX is also noteworthy at 0.88. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAGX is 7.71M, and at present, short sellers hold a 4.31% of that float. The average trading volume of JAGX on November 13, 2024 was 312.03K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
JAGX) stock’s latest price update
The stock of Jaguar Health Inc (NASDAQ: JAGX) has increased by 18.48 when compared to last closing price of 0.92.Despite this, the company has seen a gain of 4.81% in its stock price over the last five trading days. accesswire.com reported 2024-11-11 that Click here to register for investor webcast Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 financials and provide corporate updates.
JAGX’s Market Performance
Jaguar Health Inc (JAGX) has experienced a 4.81% rise in stock performance for the past week, with a -13.49% drop in the past month, and a 1.87% rise in the past quarter. The volatility ratio for the week is 9.76%, and the volatility levels for the past 30 days are at 6.27% for JAGX. The simple moving average for the past 20 days is -0.29% for JAGX’s stock, with a -75.25% simple moving average for the past 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -4.92% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.47% of loss for the given period.
Volatility was left at 6.27%, however, over the last 30 days, the volatility rate increased by 9.76%, as shares sank -6.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.68% lower at present.
During the last 5 trading sessions, JAGX rose by +4.81%, which changed the moving average for the period of 200-days by -82.62% in comparison to the 20-day moving average, which settled at $1.0932. In addition, Jaguar Health Inc saw -88.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -3.08 for the present operating margin
- 0.68 for the gross margin
The net margin for Jaguar Health Inc stands at -3.5. The total capital return value is set at -0.74. Equity return is now at value -285.01, with -62.78 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 1.72. The interest coverage ratio of the stock is -23.09.
Currently, EBITDA for the company is -33.13 million with net debt to EBITDA at -0.62. When we switch over and look at the enterprise to sales, we see a ratio of 2.77. The receivables turnover for the company is 7.47for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.10.
Conclusion
In summary, Jaguar Health Inc (JAGX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
